The Role of Circulating Tumor DNA in Decision-making of Patients With Metastatic Colorectal Cancer After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
Latest Information Update: 05 Jul 2023
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Cetuximab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Lapatinib (Primary) ; Oxaliplatin (Primary) ; Pertuzumab (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 06 Jun 2023 Status changed from not yet recruiting to recruiting, as per presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results evaluating circulating Tumor DNA as a promising biomarker for assessing treatment efficiency and guiding second-line treatment decisions in patients with mCRC, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 09 Apr 2021 New trial record